Trial reportAmerican journal of respiratory and critical care medicine2006
beta-Adrenergic receptor polymorphisms and response to salmeterol.
Trial report in American journal of respiratory and critical care medicine, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00595361 (The Effect of Beta-2 Adrenergic Polymorphisms on the Bronchoprotective Effects of Regular Salmeterol Treatment in Asthma), which is not on this map. Cited by 71 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Effect of Beta-2 Adrenergic Polymorphisms on the Bronchoprotective Effects of Regular Salmeterol Treatment in Asthma
Who cites it
71 citing papers in PubMed, 1 synthesis or guideline pooled it, 300 citations in OpenAlex.
- Genome-wide association studies of exacerbations in children using long-acting beta2-agonists.Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology · 2021Pooled it
- Predicting treatable traits for long-acting bronchodilators in patients with stable COPD.International journal of chronic obstructive pulmonary disease · 2017Trial
- Loss of salmeterol bronchoprotection against exercise in relation to ADRB2 Arg16Gly polymorphism and exhaled nitric oxide.American journal of respiratory and critical care medicine · 2013Trial
- A pharmacogenetic study of ADRB2 polymorphisms and indacaterol response in COPD patients.The pharmacogenomics journal · 2012Trial
- IL-4 receptor polymorphisms predict reduction in asthma exacerbations during response to an anti-IL-4 receptor α antagonist.The Journal of allergy and clinical immunology · 2012Trial
- Trial
- Trial
- Effect of β2-adrenergic receptor gene (ADRB2) 3' untranslated region polymorphisms on inhaled corticosteroid/long-acting β2-adrenergic agonist response.Respiratory research · 2012Trial
- Effect of beta2-adrenergic receptor polymorphism on response to longacting beta2 agonist in asthma (LARGE trial): a genotype-stratified, randomised, placebo-controlled, crossover trial.Lancet (London, England) · 2009Trial
- Trial
- Individualized Household Allergen Intervention Lowers Allergen Level But Not Asthma Medication Use: A Randomized Controlled Trial.The journal of allergy and clinical immunology. In practiceTrial
- Effects of indacaterol versus tiotropium on exercise tolerance in patients with moderate COPD: a pilot randomized crossover study.Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e TisilogiaTrial
- Lack of association between ADRB2 (Gln27Glu) variant with susceptibility, severity and salbutamol response in South Indian asthmatics.Scientific reports · 2026Article
- Effect of the Arg16Gly βAllergy · 2026Article
- The role of ADRB2 gene polymorphisms in malignancies.Molecular biology reports · 2021Review
- Activation of βArchives of pharmacal research · 2021Review
- How does race and ethnicity effect the precision treatment of asthma?Expert review of precision medicine and drug development · 2019Article
- Association of genetic variants with level of asthma control in the Arab population.Journal of asthma and allergy · 2019Article
- BPediatric research · 2018Article
- Article
11 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
19 authors at 1 institution in 1 country.
Funding
Abstract
rationaleSeveral studies suggest that patients with asthma who are homozygous for arginine at the 16th position of the beta2-adrenergic receptor may not benefit from short-acting beta-agonists.
objectivesWe investigated whether such genotype-specific effects occur when patients are treated with long-acting beta-agonists and whether such effects are modified by concurrent inhaled corticosteroid (ICS) use.
methodsWe compared salmeterol response in patients with asthma homozygous for arginine at B16 (B16Arg/Arg) with those homozygous for glycine at B16 (B16Gly/Gly) in two separate cohorts. In the first, subjects were randomized to regular therapy with salmeterol while simultaneously discontinuing ICS therapy. In the second, subjects were randomized to regular therapy with salmeterol while continuing concomitant ICS.
resultsIn both trials, B16Arg/Arg subjects did not benefit compared with B16Gly/Gly subjects after salmeterol was initiated. In the first cohort, compared with placebo, the addition of salmeterol was associated with a 51.4 L/min lower A.M. peak expiratory flow (PEF; p = 0.005) in B16Arg/Arg subjects(salmeterol, n = 12; placebo, n = 5) as compared with B16Gly/Gly subjects (salmeterol, n = 13; placebo, n = 13). In the second cohort, B16Arg/Arg subjects treated with salmeterol and ICS concurrently (n = 8) had a lower A.M. PEF (36.8 L/min difference, p = 0.048) than B16Gly/Gly subjects (n = 22) treated with the same regimen. In addition, B16 Arg/Arg subjects in the second cohort had lower FEV1 (0.42 L, p = 0.003), increased symptom scores (0.2 units, p = 0.034), and increased albuterol rescue use (0.95 puffs/d, p = 0.004) compared with B16Gly/Gly subjects.
conclusionsRelative to B16Gly/Gly patients with asthma, B16Arg/Arg patients with asthma may have an impaired therapeutic response to salmeterol in either the absence or presence of concurrent ICS use. Investigation of alternate treatment strategies may benefit this group.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.